多发肋骨骨折合并局部反常呼吸开展胸部护板的价值及对预后影响

Value of thoracic shield and its effect on prognosis were carried out in combination of multiple rib fractures and partial anomalous breathing

目的：评价Chrisofix胸部护板在治疗多发肋骨骨折并局部反常呼吸中的临床效果。方法：选择我院2014年3月-2017年5月收治的53例多发肋骨骨折并局部反常呼吸患者为本次研究对象，根据治疗方法不同分为对照组（26例）与观察组（27例），对照组按照常规治疗方法，观察组采用Chrisofix胸部护板治疗，对比2组患者VAS评分、首次离床时间、住院时间及并发症情况。结果：2组患者在入院时VAS评分比较无统计学差异，P〉0．05，入院24小时、入院48小时、入院72小时、第7天的VAS评分均存在统计学意义，P〈0．05；观察组首次离床时间早于对照组，住院时间少于对照组，并发症总发生率小于对照组，组间数据差异有统计学意义，P〈0．05。结论：对多发肋骨骨折并局部反常呼吸患者开展Chrisofix胸部护板治疗，能够有效降低患者疼痛度，缩短离床时间，减少住院时间，且并发症少，能显著提升预后。

Objective： To evaluate the clinical effect of Chrisofix chest plate in the treatment of multiple rib fractures and partial abnormal breathing. Methods： From March 2016 to May 2017 were 53 cases of multiple fractured ribs and local abnormal breathing patient as the study object, according to different therapeutic methods were divided into control group （26 cases） and observation group （27 cases） and control group according to the conventional treatment methods, treatment with observation group Chrisofix chest protector, VAS score, compared two groups of patients before it＇s time to bed for the first time, length of hospital stay, and complications. Results： The VAS scores were no statistically significant difference between the two groups at admission, p 〉 0.05, the admission of 24h, 48h hospitaliza- tion, 72h admission, and the 7th day of VAS score were statistically significant p 〈 0.05. Observation group before it＇s time to bed for the first time earlier than the control group, the length of hospital stay and the control group, less data difference between incidence of complications, the total was less than the control group, the group has statistically significant （p 〈 O. 05）. Conclusion： In patients with multi- ple fractured ribs and local abnormal breathing Chrisofix chest plate treatment, could effectively reduce the patients pain degree, shorten from bed time, reduce the length of hospital stay, and less complications, could significantly improve the prognosis.